17409841

Source:http://linkedlifedata.com/resource/pubmed/id/17409841

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006754, umls-concept:C0006826, umls-concept:C0007131, umls-concept:C0008976, umls-concept:C0205179, umls-concept:C0205390, umls-concept:C0246415, umls-concept:C0280100, umls-concept:C1176309, umls-concept:C1513822, umls-concept:C1880171
pubmed:issue	2
pubmed:dateCreated	2007-4-5
pubmed:abstractText	This phase I study was performed to determine the dose-limiting toxicity and maximum tolerated dose (MTD) of docetaxel in combination with bortezomib in patients with advanced non-small cell lung cancer (NSCLC) or other solid tumors.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101274235
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Boronic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Pyrazines, http://linkedlifedata.com/resource/pubmed/chemical/Radiation-Sensitizing Agents, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/bortezomib, http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1556-1380
pubmed:author	pubmed-author:DaviesAngela MAM, pubmed-author:DoroshowJames HJH, pubmed-author:GandaraDavid RDR, pubmed-author:GumerlockPaul HPH, pubmed-author:KashalaOscarO, pubmed-author:KoczywasMarianaM, pubmed-author:LaraPrimo NPNJr, pubmed-author:LauDerick H MDH, pubmed-author:LenzHeinz JosefHJ, pubmed-author:LongmateJeffJ, pubmed-author:QuinnDavid IDI, pubmed-author:SchenkeinDavidD
pubmed:issnType	Electronic
pubmed:volume	1
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	126-34
pubmed:dateRevised	2008-5-6
pubmed:meshHeading	pubmed-meshheading:17409841-Adult, pubmed-meshheading:17409841-Aged, pubmed-meshheading:17409841-Antineoplastic Agents, pubmed-meshheading:17409841-Boronic Acids, pubmed-meshheading:17409841-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:17409841-Disease Progression, pubmed-meshheading:17409841-Dose-Response Relationship, Drug, pubmed-meshheading:17409841-Drug Administration Routes, pubmed-meshheading:17409841-Drug Therapy, Combination, pubmed-meshheading:17409841-Female, pubmed-meshheading:17409841-Follow-Up Studies, pubmed-meshheading:17409841-Humans, pubmed-meshheading:17409841-Lung Neoplasms, pubmed-meshheading:17409841-Male, pubmed-meshheading:17409841-Middle Aged, pubmed-meshheading:17409841-Pyrazines, pubmed-meshheading:17409841-Radiation-Sensitizing Agents, pubmed-meshheading:17409841-Survival Rate, pubmed-meshheading:17409841-Taxoids, pubmed-meshheading:17409841-Treatment Outcome
pubmed:year	2006
pubmed:articleTitle	Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
pubmed:affiliation	University of California, Davis Cancer Center, Sacramento, California 95817, USA. Primo.Lara@ucdmc.ucdavis.edu
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase I